# CRT-Guanfacine for SPD

> **NCT02524899** · PHASE2 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 45 (actual)

## Conditions studied

- Schizotypal Personality Disorder
- SPD

## Interventions

- **BEHAVIORAL:** Cognitive Remediation Therapy
- **DRUG:** Guanfacine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02524899
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2017-01-10
- **Final completion:** 2017-01-10
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02524899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02524899, "CRT-Guanfacine for SPD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02524899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*